Amgen Inc (AMGN)
294.86
+4.96
(+1.71%)
USD |
NASDAQ |
Nov 22, 14:43
Amgen Revenue (Annual): 28.19B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 28.19B |
December 31, 2022 | 26.32B |
December 31, 2021 | 25.98B |
December 31, 2020 | 25.42B |
December 31, 2019 | 23.36B |
December 31, 2018 | 23.75B |
December 31, 2017 | 22.85B |
December 31, 2016 | 22.99B |
December 31, 2015 | 21.66B |
December 31, 2014 | 20.06B |
December 31, 2013 | 18.68B |
December 31, 2012 | 17.26B |
December 31, 2011 | 15.58B |
December 31, 2010 | 15.05B |
December 31, 2009 | 14.64B |
December 31, 2008 | 15.00B |
December 31, 2007 | 14.77B |
December 31, 2006 | 14.27B |
December 31, 2005 | 12.43B |
December 31, 2004 | 10.55B |
December 31, 2003 | 8.356B |
Date | Value |
---|---|
December 31, 2002 | 5.523B |
December 31, 2001 | 4.016B |
December 31, 2000 | 3.448B |
December 31, 1999 | 3.204B |
December 31, 1998 | 2.642B |
December 31, 1997 | 2.346B |
December 31, 1996 | 2.198B |
December 31, 1995 | 1.904B |
December 31, 1994 | 1.62B |
December 31, 1993 | 1.355B |
December 31, 1992 | 1.080B |
December 31, 1991 | 679.80M |
March 31, 1991 | 381.20M |
March 31, 1990 | 190.40M |
March 31, 1989 | 70.20M |
March 31, 1988 | 44.30M |
March 31, 1987 | 29.80M |
March 31, 1986 | 21.10M |
March 31, 1985 | 7.10M |
March 31, 1984 | 2.80M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
23.36B
Minimum
2019
28.19B
Maximum
2023
25.86B
Average
25.98B
Median
2021
Revenue (Annual) Benchmarks
Johnson & Johnson | 85.16B |
Eli Lilly and Co | 34.12B |
Merck & Co Inc | 60.12B |
Regeneron Pharmaceuticals Inc | 13.12B |
Viking Therapeutics Inc | -- |